文献速递脑血管病

药物洗脱支架与裸金属支架在有症状的高级别颅内动脉粥样硬化性狭窄患者中的比较:一项随机临床试验

Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项前瞻性、多中心、开放标签、结局评估设盲的随机临床试验于2015年4月27日至2018年11月16日在中国16个医疗中心开展,纳入263例有症状的高级别颅内动脉粥样硬化性狭窄患者,按1:1随机接受药物洗脱支架(DES)或裸金属支架(BMS)治疗。结果显示,DES组1年支架内再狭窄(ISR)率低于BMS组(10[9.5%] vs 32[30.2%];OR 0.24;95%CI 0.11-0.52;P<.001),第31天至1年的缺血性卒中复发率也显著低于BMS组(1[0.8%] vs 9[6.9%];HR 0.10;95%CI 0.01-0.80;P=.03);两组术后30天内任何卒中或死亡发生率无显著差异(10[7.6%] vs 7[5.3%];OR 1.45;95%CI 0.54-3.94;P=.46)。

要点

  • DES组1年ISR率为9.5%,低于BMS组的30.2%(OR 0.24;95%CI 0.11-0.52;P<.001)。
  • DES组第31天至1年缺血性卒中复发率为0.8%,低于BMS组的6.9%(HR 0.10;95%CI 0.01-0.80;P=.03)。
  • 两组术后30天内任何卒中或死亡发生率无显著差异(7.6% vs 5.3%;OR 1.45;95%CI 0.54-3.94;P=.46)。

核心结论

  • 与BMS相比,DES降低了有症状的高级别ICAS患者的ISR风险和缺血性卒中复发风险。
  • 原文指出,仍需进一步研究DES的安全性和有效性。

研究设计与样本

  • 前瞻性、多中心、开放标签、结局评估设盲的随机临床试验,于2015年4月27日至2018年11月16日在中国16个医疗中心开展。
  • 纳入有症状的高级别ICAS患者,按1:1随机分配接受DES(NOVA颅内西罗莫司洗脱支架系统)或BMS(Apollo颅内支架系统)治疗,随访1年。
  • 共263例参与者纳入分析(194例男性[73.8%];中位[IQR]年龄58[52-65]岁),DES组132例,BMS组131例。
  • 意向性分析于2021年4月1日至5月22日进行。

主要发现

  • 1年ISR率DES组为10[9.5%],BMS组为32[30.2%](OR 0.24;95%CI 0.11-0.52;P<.001)。
  • 第31天至1年缺血性卒中复发率DES组为1[0.8%],BMS组为9[6.9%](HR 0.10;95%CI 0.01-0.80;P=.03)。
  • 术后30天内任何卒中或死亡发生率DES组为10[7.6%],BMS组为7[5.3%](OR 1.45;95%CI 0.54-3.94;P=.46),无显著差异。

关键数值与推荐

  • 主要疗效终点为术后1年内ISR,定义为植入支架内或紧邻支架处(5 mm以内)管腔直径狭窄大于50%。
  • 主要安全终点为术后30天内任何卒中或死亡。

局限性

  • 原文结论指出,仍需进一步研究DES的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In-stent restenosis (ISR) is the primary reason for stroke recurrence after intracranial stenting in patients who were treated with a standard bare-metal stent (BMS). Whether a drug-eluting stent (DES) could reduce the risk of ISR in intracranial atherosclerotic stenosis (ICAS) remains unclear. OBJECTIVE: To investigate whether a DES can reduce the risk of ISR and stroke recurrence in patients with symptomatic high-grade ICAS. DESIGN, SETTINGS, AND PARTICIPANTS: A prospective, multicenter, open-label randomized clinical trial with blinded outcome assessment was conducted from April 27, 2015, to November 16, 2018, at 16 medical centers in China with a high volume of intracranial stenting. Patients with symptomatic high-grade ICAS were enrolled, randomized, and followed up for 1 year. Intention-to-treat data analysis was performed from April 1 to May 22, 2021. INTERVENTIONS: Patients were randomly assigned to receive DES (NOVA intracranial sirolimus-eluting stent system) or BMS (Apollo intracranial stent system) treatment in a 1:1 ratio. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was ISR within 1 year after the procedure, which was defined as stenosis that was greater than 50% of the luminal diameter within or immediately adjacent to (within 5 mm) the implanted stent. The primary safety end point was any stroke or death within 30 days after the procedure. RESULTS: A total of 263 participants (194 men [73.8%]; median [IQR] age, 58 [52-65] years) were included in the analysis, with 132 participants randomly assigned to the DES group and 131 to the BMS group. The 1-year ISR rate was lower in the DES group than in the BMS group (10 [9.5%] vs 32 [30.2%]; odds ratio, 0.24; 95% CI, 0.11-0.52; P < .001). The DES group also had a significantly lower ischemic stroke recurrence rate from day 31 to 1 year (1 [0.8%] vs 9 [6.9%]; hazard ratio, 0.10; 95% CI, 0.01-0.80; P = .03). No significant difference in the rate of any stroke or death within 30 days was observed between the DES and BMS groups (10 [7.6%] vs 7 [5.3%]; odds ratio, 1.45; 95% CI, 0.54-3.94; P = .46). CONCLUSIONS AND RELEVANCE: This trial found that, compared with BMSs, DESs reduced the risks of ISR and ischemic stroke recurrence in patients with symptomatic high-grade ICAS. Further investigation into the safety and efficacy of DESs is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02578069.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Jia B, Zhang X, Ma N, et al. Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 34982098. doi:10.1001/jamaneurol.2021.4804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。